CRA (CRAI) Q1 2026 Earnings Call Transcript

CRA International posted record quarterly revenue of $201 million, up 10.5% year over year, with non-GAAP EBITDA of $23.2 million and utilization rising to 77%. Growth was broad-based across geographies and practices, led by double-digit gains in Energy, Finance, Forensic Services, and Life Sciences, while Antitrust & Competition Economics hit a new quarterly high amid stronger M&A activity. Management reaffirmed fiscal 2026 guidance, raised the revolver to $300 million, and returned $25.3 million to shareholders via dividends and buybacks.

Analysis

CRAI is signaling something more durable than a single strong quarter: its earnings power is becoming less cyclical because the mix is tilting toward complexity-driven work where demand is tied to dispute intensity, deal scrutiny, regulatory friction, and data-intensive forensic needs. That creates a longer-duration revenue tail than a simple M&A beta play, and it also means the company can monetize complexity even if headline transaction volumes cool, which is the key second-order positive the market may be underestimating.

The important margin insight is that the business is still absorbing talent-investment drag while utilization remains high and pricing is moving up, which implies operating leverage is being masked by deliberate front-end investment. If the hiring pipeline continues to convert, the forgivable-loan amortization and retention spend should behave more like a growth tax than a structural margin ceiling; that matters because the market often capitalizes these costs as if they were permanent when they may actually be setting up a second-half or next-year step-up in EBITDA conversion.

The main risk is not demand—it's execution on redeploying incremental capacity without diluting pricing discipline. A softer M&A tape would hit one practice, but the broader vulnerability is that management is implicitly promising to keep adding expensive talent faster than revenue can ramp, so any slip in utilization or pricing realization would quickly expose the fixed-cost base. On the other hand, AI is likely a net demand multiplier for this franchise, because model-assisted analysis raises the volume of questions clients can ask while simultaneously increasing the need for defensible expert judgment; that is a favorable setup for high-end consultancies with credibility moats.

From a stock perspective, the setup looks stronger on a 6-12 month basis than on a 1-2 quarter basis because the next leg of upside should come from rate realization, continued utilization at the high-70s, and easier comps for some of the investment drag. The asymmetric setup is that the market may still be valuing CRAI like a normal professional-services compounder rather than a scarcity asset in litigation, antitrust, and regulatory advisory, which deserves a premium multiple if growth remains broad-based and self-funded.

Key Decisions for Investors

• Long CRAI common for 6-12 months on pullbacks: use any post-earnings or market-wide weakness to build a position, targeting a rerating if the market starts capitalizing utilization + pricing + AI-assisted demand as a durable growth compounder.
• Buy CRAI Jan-2027 calls or call spreads: preferred vehicle if you want upside to continued high-70s utilization and second-half margin conversion while limiting downside from any temporary growth lull; best risk/reward if implied vol stays contained.
• Pair trade: long CRAI / short a lower-quality cyclical consulting or services name with more revenue dependence on discretionary corporate activity; CRAI should outperform if litigation, antitrust, and forensic demand stay elevated while broader consulting cools.
• If already long, hedge with a modest short-dated put spread against a 1-2 quarter utilization miss: the stock is vulnerable if headcount growth outpaces revenue ramp and pricing fails to show through by mid-year.
• Watch for a second entry point after the next quarter if rate realization still hasn’t fully flowed through; that would likely be the best timing to add because the market may then be underestimating FY27 margin leverage.